Literature DB >> 16858166

Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone.

Vanina Bongard1, Delay Marc, Vigreux Philippe, Montastruc Jean-Louis, Lapeyre-Mestre Maryse.   

Abstract

The aim of this observational prospective study was to assess the incidence rate and the characteristics of adverse drug reactions (ADRs) induced by amiodarone during the long-term follow-up of 98 French patients. Inclusions were performed between March 1994 and April 1997. Eligible patients were consecutive outpatients for whom amiodarone was initiated for the first time. The treatment had to be taken for at least 6 months if no ADR required its withdrawal. A cohort of 57 men and 41 women, mean age 72.6 years (SD: 8.6), was followed for a mean period of 38 months. The incidence rate of ADRs during the overall follow-up period was 13.91 cases for 100 person-years. Recorded ADRs were 13 hypothyroidism (incidence rate for 100 person-years: 4.61 [95% confidence interval: 4.58-4.63], 5 hyperthyroidism (1.62 [1.60-1.63]), 10 bradycardia and/or conduction ADRs (3.48 [3.46-3.50]), 7 photosensitivity (2.27 [2.25-2.28]), 1 storage disease (0.33 [0.32-0.33]), 3 interstitial pneumonitis (0.97 [0.96-0.98]), 2 peripheral neuropathies (0.65 [0.64-0.66]), 1 tremor (0.32 [0.32-0.33]) and 1 gastrointestinal disturbances (0.32 [0.32-0.33])). Thyroid and cardiac ADRs occurred mainly during the first 6 months. According to the French system of pharmacovigilance, 27 ADRs were "probable/likely" and 14 were "possible." Hypothyroidism, cardiac ADRs, and photosensitivity were the most frequent ADRs. None of the ADRs had a fatal outcome in this study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16858166     DOI: 10.1097/00045391-200607000-00007

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  9 in total

1.  Management of amiodarone-related thyroid problems.

Authors:  Shashithej K Narayana; David R Woods; Christopher J Boos
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

Review 2.  Drug-induced photosensitivity: culprit drugs, management and prevention.

Authors:  Aaron M Drucker; Cheryl F Rosen
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

3.  Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study.

Authors:  Chun-Jui Huang; Po-Ju Chen; Jing-Wen Chang; De-Feng Huang; Shih-Lin Chang; Shih-Ann Chen; Tjin-Shing Jap; Liang-Yu Lin
Journal:  Int J Clin Pharm       Date:  2014-02-11

4.  Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France.

Authors:  Mariam Molokhia; Atul Pathak; Maryse Lapeyre-Mestre; Laetitia Caturla; Jean Louis Montastruc; Paul McKeigue
Journal:  Br J Clin Pharmacol       Date:  2008-07-15       Impact factor: 4.335

Review 5.  Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.

Authors:  Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Drug Des Devel Ther       Date:  2011-01-06       Impact factor: 4.162

Review 6.  Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.

Authors:  Paula Trigo; Gregory W Fischer
Journal:  Clin Interv Aging       Date:  2011-12-30       Impact factor: 4.458

Review 7.  Drug-Induced Interstitial Lung Disease: A Systematic Review.

Authors:  Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri
Journal:  J Clin Med       Date:  2018-10-15       Impact factor: 4.241

Review 8.  Adverse reactions of Amiodarone.

Authors:  Ruben Ml Colunga Biancatelli; Viviana Congedo; Leonardo Calvosa; Marco Ciacciarelli; Alessandro Polidoro; Luigi Iuliano
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

9.  Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics.

Authors:  Arlene Tave; Earl Goehring; Vibha Desai; Chuntao Wu; Rhonda L Bohn; Sally G Tamayo; Nicholas Sicignano; Juhaeri Juhaeri; Judith K Jones; Sheila R Weiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-05-04       Impact factor: 2.890

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.